Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PROTAC Mediated Structure-Function Disruption of CD26 A Therapeutic Strategy for Driver Negative NSCLC

ABSTRACT: P4-3 is a PROTAC designed to induce degradation of CD26, a transmembrane glycoprotein with dual oncogenic functions overexpressed in NSCLC. Here, we employed label-free quantitative proteomics to characterize its global proteomic impact on H460 cells. Bottom-up proteomics was performed on samples treated with DMSO or P4-3 (24 hours, 6 biological replicates per group) to assess proteome-wide alterations.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Neoplastic Cell, Lung

DISEASE(S): Lung Cancer

SUBMITTER: Bohao Liu

LAB HEAD: Bohao Liu

PROVIDER: PXD068995 | Pride | 2025-10-28

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Results.zip	Other
	XC06404DA_C_1_Slot1-1_1_20740.d.zip	Other
	XC06404DA_C_2_Slot1-1_1_20741.d.zip	Other
	XC06404DA_C_3_Slot1-1_1_20742.d.zip	Other
	XC06404DA_Y_1_Slot1-1_1_20736.d.zip	Other

Items per page:

1 - 5 of 8

Similar Datasets

Proteomics analysis of lipid-induced granules

Project description:During the processes of MAFLD and MASH, DDX49 undergoes liquid-liquid phase separation. Subsequently, we used OA/PA (2:1) to simulate the MASH model in vitro. After treating HHL5 cells with OA/PA for 24 hours, we separated the lipid-organized particles of DDX49 by differential centrifugation. To investigate the composition of these particles and study their functions, we conducted a 10-fold proteomic analysis.

2026-01-09 | PXD064747 | Pride

HCT116-TGTA-proteomic profiling

Project description:HCT116 cells were treated with or without 50 μM TGTA for 24 hours. Cells were collected and the proteomes were then extracted for proteomic analysis.

2025-07-16 | PXD063241 | Pride

Proteotyping rare amyloidosis disease by photocatalytic proteomics profiling

Project description:we present a photocatalytic proteomic method, named Amyloid-ID, as a quantitative approach to identify the composition of amyloid deposits for clinical proteotyping of amyloidosis diseases. Amyloid-ID is enabled by a photosensitized probe analogous to the pan-amyloid sensor Thioflavin T. We show this probe photocatalyzes gradient protein labeling originated from amyloid deposits and enriches them from tissue in a spatially-resolved manner. Next, we exemplify its application in proteotyping the pathogenic protein of the rare Laryngeal Amyloidosis (LA).

2025-01-25 | PXD059313 | Pride

proteomic quantitative analysis of cell supernatants from Ddx49f/f and Ddx49hep-/-

Project description:In our study, we demonstrated that the supernatant components secreted by hepatocytes are capable of activating hepatic stellate cells and promoting their differentiation into myofibroblasts. To identify the secretome regulated by DDX49 in hepatocytes, primary liver cells isolated from both control and DDX49-knockout mice were subjected to OA/PA stimulation for 24 hours. Subsequently, the conditioned media were collected and subjected to 10X high-depth proteomic quantitative analysis.

2026-01-09 | PXD064823 | Pride

Microscope-Free Microdissection of Amyloid Plagues in Alzheimer’s Disease Tissue via Single Electron Transfer Photocatalysis

Project description:Amyloid protein deposit, like Aβ plaques, is a pathological hallmark of Alzheimer’s disease (AD). While plenty of amyloid imaging reagents available for diagnosis, their composition associated with disease etiology is challenging to analyze in intact tissue sample. Herein, we report an amyloid-targeting probe to photocatalyze in-situ labeling and profiling of Aβ plaques in AD brain tissue via single electron transfer (SET) mechanism. First, we render this amyloid probe with photocatalytic labeling function by fragment fusion of classical scaffolds of fluorescent amyloid sensors. Second, we demonstrate its labeling selectivity to amyloid proteins over monomer counterparts. Mechanistically, we show spatially resolved labeling is driven by the short-lived SET photocatalytic process. Finally, we use this probe to capture and profile the composition of amyloid plagues in Alzheimer’s disease brain tissue. Surpassing other AD proteomics datasets, our work spatially resolves pathogenic Aβ and typical AD biomarkers as top-ranked hits. Together, the short-lived SET-driven photocatalysis spatially restrains protein labeling to occur in ultra-proximity to amyloids, allowing for microscope-free amyloid tissue microdissection at molecular level.

2025-01-13 | PXD059374 | Pride

FGF13 in septic lung injury: A regulator of the ERK/aerobic glycolysis axis in the inflammatory state

Project description:HEK293T cells were transfected with Flag-FGF13 plasmids, and cells were performed with immunoprecipitation by Flag antibody or IgG (CST, 3900, USA) with protein A/G beads (Meck, LSKMAGAG10, USA). Coimmunoprecipitation was carried out in HEK293T cells and visualized with silver staining by using the beyotime fast silver stain kit (P0017S). Then mass spectrometry was used to detect all the proteins connected with Flag-FGF13. The assay was carried by Shanghai Bioprofile Technology Company Ltd. In brief, the gradient consisted of 5~35% (v/v) acetonitrile in 0.1% (v/v) formic acid at a flow rate of 200 nL/min for 10 min, 35~100% (v/v) acetonitrile in 0.1% (v/v) formic acid at a flow rate of 200 nL/min for 2 min and 100% acetonitrile in 0.1% formic acid at a flow rate of 200 nL/min for 8 min. The eluted peptides were ionized and introduced into a Thermo Fisher LTQ Velos Pro mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) using a Proxeon nanoelectrospray ion source. Survey full-scan MS spectra (from m/z 200~1800) were acquired. A full mass spectrum (m/z 200~1800) was followed by fragmentation of the ten most abundant peaks, using 35% of the normalized collision energy for obtaining MS/MS spectra. All peptide assignments were verified by manual inspection. The information about the proteins connected with Flag-FGF13 was summarized in Supplementary materials: Proteins connect with Flag-FGF13.‘’

2025-12-17 | PXD057743 | Pride

Cardiomyocyte OTUD1 drives diabetic cardiomyopathy via directly deubiquitinating AMPKα2 to inhibit AMPK activity and induce mitochondrial dysfunctionCardiomyocyte OTUD1 drives diabetic cardiomyopathy via directly deubiquitinating AMPKα2 to inhibit AMPK activity and induce mitochondrial dysfunction

Project description:The sample was removed from-80℃ and melted on ice. An appropriate amount of TEAB was added to adjust pH 8.0.5 μ L of suspension was used for SDS-PAGE testing.

2025-06-11 | PXD061479 | Pride

TNFRSF11B-modified umbilical cord mesenchymal stem cells as a novel strategy for bone-related diseases by suppressing osteoclast activity

Project description:This study explored the proteomic changes in UCMSCs cells following TNFRSF11B gene overexpression. Stable overexpression of TNFRSF11B in UCMSCs via lentiviral transduction. Proteomic analysis was conducted on the conditioned medium from control UCMSCs and TNFRSF11B-overexpressing UCMSCs. Transfected cells were seeded in culture flasks, and the culture medium was collected after 2 days and rapidly frozen in -80℃. The differential protein expression profile linked to TNFRSF11B overexpression in UCMSCs was analyzed using 4D label-free proteomics (PTM Bio, Hangzhou).

2025-05-21 | PXD062832 | Pride

Targeted therapies restore skin barrier function and associated proteomics in atopic dermatitis

Project description:Background: Atopic dermatitis (AD) is characterized by skin barrier dysfunction. The impact of targeted therapies on skin barrier function and associated barrier protein changes remains not fully identified. Objective: To investigate the skin barrier function and proteomics in AD before and after different targeted therapies. Method: 15 healthy controls and 29 adult patients with moderate-to-severe AD were enrolled. AD patients were randomized into two groups. One group received dupilumab (N = 14) and the other received abrocitinib (N = 15). Clinical assessments and skin barrier parameters (transepidermal water loss [TEWL] and hydration) were measured at baseline, 4 weeks, and 12 weeks of treatment. Skin tape strips were collected for four-dimensional data-independent acquisition-based proteomics. Results: Both therapies improved skin barrier function, with abrocitinib showing greater effects on decreasing TEWL in the non-lesional skin. The proteomic analysis identified 1237 lesional and 785 non-lesional differentially expressed proteins (DEPs) between AD patients and healthy controls, especially in pathways related to ceramide metabolism, neurobiology, and keratinocyte biology. Treatment with abrocitinib resulted in more DEPs and significantly upregulated proteins associated with the epidermal barrier while downregulating immunological and itch-related proteins. It also increased key barrier proteins (filaggrin-2 and loricrin) in lesional skin, which was not shown in the dupilumab group. Both treatments regulated specific proteins in non-lesional skin, such as grancalcin and phospholipase D3. Conclusion: The study suggests that both targeted therapies improve the skin barrier function in AD, but they have different effects on barrier proteins, with abrocitinib having stronger effects.

2025-04-19 | PXD055561 | Pride

Sac1 interaction proteomics of ALFA Sac1 and mutants

Project description:Sphingolipids are structural membrane components that also function in cellular stress responses. The serine palmitoyl-transferase (SPT) catalyzes the rate limiting step in sphingolipid biogenesis. Its activity is tightly regulated through multiple bind-ing partners, including Tsc3, Orm proteins, ceramides, and the phosphatidylinositol-4-phosphate (PI4P) phosphatase Sac1. The structural organization and regulatory mechanisms of this complex are not yet understood. Here, we report the high-resolution cryo-EM structures of the yeast SPT in complex with Tsc3 and Orm1 (SPOT) as dimers and monomers and a monomeric complex further carrying Sac1 (SPOTS). In all complexes, the tight interaction of the down-stream metabolite ceramide and Orm1 reveals the ceramide dependent inhibition. Additionally, observation of ceramide and ergosterol binding suggests a co-regulation of sphingolipid biogenesis and sterol metabolism within the SPOTS com-plex.

2023-10-24 | PXD044586 | Pride